FDA Continues Site Tours Program
The agency is continuing CDER’s Regulatory Project Management Site Tours and Regulatory Interaction Program.
On Feb. 9, 2016, FDA’s Center for Drug Evaluation and Research (CDER) announced the continuation of the Regulatory Project Management Site Tours and Regulatory Interaction Program, also known as the Site Tours Program. The program is part of CDER’s training and development programs designed to promote high performance and enhance review efficiency by providing firsthand exposure to the industry’s drug development processes.
The Site Tours Program allows small groups of regulatory project managers to observe the manufacturing operations of participating pharmaceutical companies in order to gain more understanding of manufacturing processes. The regulatory project managers also participate in workshops with industry counterparts to learn about a team approach to drug development.
Pharmaceutical companies interested in participating in the program should submit proposed agendas to FDA by April 11, 2016.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
